Lorraine V. Kalia

12.8k citations

87 papers · 8.9k indexed · 2 hit papers · h-index 33

Neurology top 0.1%
- Parkinson's Disease Mechanisms and Treatments 44
- Neurological disorders and treatments 30
- Neurological diseases and metabolism 7
- Botulinum Toxin and Related Neurological Disorders 6
Cellular and Molecular Neuroscience top 0.5%
- Neuroscience and Neuropharmacology Research 12
- Nuclear Receptors and Signaling 12
- Genetic Neurodegenerative Diseases 10
Neurology top 0.5%
- Parkinson's Disease Mechanisms and Treatments 44
- Neurological disorders and treatments 30
- Neurological diseases and metabolism 7
- Botulinum Toxin and Related Neurological Disorders 6
Biological Psychiatry top 2%
Developmental Neuroscience top 2%
Physiology
- Lysosomal Storage Disorders Research 6

Co-authors: Anthony E. Lang Michael W. Salter Suneil K. Kalia Jonathan M. Brotchie Pamela J. McLean Andrés M. Lozano James B. Koprich Paul O’Connor
Cited by: Neurology Cellular and Molecular Neuroscience
Journals: Nature (1 paper)The Lancet (1 paper)Journal of Biological Chemistry (1 paper)
Partner nations: Canada United States Germany

In The Last Decade

Lorraine V. Kalia

79 papers receiving 8.8k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Lorraine V. Kalia

Since Specialization

Citations

This map shows the geographic impact of Lorraine V. Kalia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lorraine V. Kalia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lorraine V. Kalia more than expected).

Fields of papers citing papers by Lorraine V. Kalia

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lorraine V. Kalia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lorraine V. Kalia. The network helps show where Lorraine V. Kalia may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Lorraine V. Kalia, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Lorraine V. Kalia Line = papers co-authored together Lorraine V. Kalia links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Characterization of motor and non-motor features associated with bilateral nigral degeneration due to A53T alpha-synuclein in female rats Scientific Reports ·Laura Kondrataviciute,Minesh Kapadia,Hien Chau,Cherisse Tan,POLLY OU,Ritisha Mukherjee,Sarah Hui,Sabika Jafri,Jimmy George,Ivan Skelin,Taufik A. Valiante,L. Milosevic,Lorraine V. Kalia,Suneil K. Kalia	2026	0
2	Vascular models of Alzheimer's disease: An overview of recent in vitro models of the blood-brain barrier Neurobiology of Disease ·Lily E Takeuchi,Lorraine V. Kalia,Craig A. Simmons	2025	2
3	The Management of Parkinson's Disease Before, during and after Pregnancy—an MDS Scientific Issues Committee Review Movement Disorders Clinical Practice ·Alexander Lehn,Jee‐Young Lee,Giorgia Sciacca,Scott D. Patterson,Adam Morton,Paul Pun,Walaa A. Kamel,Marina Picillo,Bart Post,Eng‐King Tan,Tamine Capato,Bastiaan R. Bloem,Manon Auffret,Annelien M. Oosterbaan,Willanka Kapelle,Michiko Kimura Bruno,Lorraine V. Kalia,Jeffrey H. Kordower,Daniela Berg	2025	0
4	Re-examining the pathobiological basis of gait dysfunction in Parkinson’s disease Trends in Neurosciences ·Newton Cho,Lorraine V. Kalia,Suneil K. Kalia	2025	2
5	Levodopa Equivalent Daily Dosage: Geographical Variations and Real‐Life Modules in Parkinson's Disease Movement Disorders Clinical Practice ·Prashanth Lingappa Kukkle,Lorraine V. Kalia,Ahsan Habib,Priya Jagota,Rajeev Ojha,Rukmini Mridula Kandadai,Soaham Desai,Manjula Caldera,Darshana Sirisena,Divyani Garg,Tiago Mestre,Rosy Neupane,Suppata Maytharakcheep,Kanyawat Sanyawut,Rupam Borgohain	2024	0
6	International Parkinson and Movement Disorder Society Viewpoint on Biological Frameworks of Parkinson's Disease: Current Status and Future Directions Movement Disorders ·Lorraine V. Kalia,Daniela Berg,Jeffery H. Kordower,Kathleen M. Shannon,John‐Paul Taylor,Francisco Cardoso,Jennifer G. Goldman,Beomseok Jeon,Wassilos G. Meissner,Marina A.J. Tijssen,David J. Burn,Victor S.C. Fung	2024	8
7	Basic Science in Movement Disorders: Fueling the Engine of Translation into Clinical Practice Movement Disorders ·Tiago F. Outeiro,Lorraine V. Kalia,Erwan Bézard,Juan E. Ferrario,Chin‐Hsien Lin,Mohamed Salama,David G. Standaert,Lolade Taiwo,Ryōsuke Takahashi,Miquel Vila,Brit Mollenhauer,Per Svenningsson	2024	1
8	Feasibility of Simon 2-Stage Futility Trials in Early Parkinson Disease Neurology ·Marcus Koch,Lorraine V. Kalia,Justyna R. Sarna,Daryl Wile,Tiago Mestre,Michael G. Schlossmacher,Jop Mostert,Eva Strijbis,Bernard M.J. Uitdehaag,Amber Salter,Gary Cutter	2024	0
9	If Art Were a Drug: Implications for Parkinson’s Disease Journal of Parkinson s Disease ·Priti Gros,Blanca T. M. Spee,Bastiaan R. Bloem,Lorraine V. Kalia	2024	6
10	Disrupting the α-synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models of Parkinson’s disease Nature Communications ·Satra Nim,Darren M. O’Hara,Carles Corbi‐Verge,Albert Perez‐Riba,Kazuko Fujisawa,Minesh Kapadia,Hien Chau,Federica Albanese,Grishma Pawar,Mitchell L. de Snoo,Sophie G. Ngana,Ji‐Sun Kim,Omar M. A. El‐Agnaf,Enrico Rennella,Lewis E. Kay,Suneil K. Kalia,Lorraine V. Kalia,Philip M. Kim	2023	32
11	Recent Advances in the Development of Stem‐Cell‐Derived Dopaminergic Neuronal Transplant Therapies for Parkinson's Disease Movement Disorders ·Peter A. Barbuti,Roger A. Barker,Patrik Brundin,Serge Przedborski,Stella M. Papa,Lorraine V. Kalia,Hideki Mochizuki	2021	39
12	C-terminus of Hsp70 Interacting Protein (CHIP) and Neurodegeneration: Lessons from the Bench and Bedside Current Neuropharmacology ·Sivakami Mylvaganam,Rebecca Earnshaw,Gregory Heymann,Suneil K. Kalia,Lorraine V. Kalia	2020	12
13	Bcl-2-associated athanogene 5 (BAG5) regulates Parkin-dependent mitophagy and cell death Cell Death and Disease ·Mitchell L. de Snoo,Erik Loewen Friesen,Yu Tong Zhang,Rebecca Earnshaw,Geneviève Dorval,Minesh Kapadia,Darren M. O’Hara,Victoria Agapova,Hien Chau,Ornella Pellerito,Matthew Y. H. Tang,Xinzhu Wang,Gerold Schmitt‐Ulms,Thomas M. Durcan,Edward A. Fon,Lorraine V. Kalia,Suneil K. Kalia	2019	38
14	Deep brain stimulation: potential for neuroprotection Annals of Clinical and Translational Neurology ·Chris McKinnon,Priti Gros,Darrin J. Lee,Clement Hamani,Andrés M. Lozano,Lorraine V. Kalia,Suneil K. Kalia	2018	58
15	The GBA p.Trp378Gly mutation is a probable French‐Canadian founder mutation causing Gaucher disease and synucleinopathies Clinical Genetics ·Jennifer A. Ruskey,Sirui Zhou,Raoul Santiago,L.‐A. Franche,Armaghan Alam,Léanne Roncière,Dan Spiegelman,Edward A. Fon,Jean‐François Trempe,Lorraine V. Kalia,Ronald B. Postuma,Nicolas Dupré,Georges‐Étienne Rivard,Sarit Assouline,Dominick Amato,Ziv Gan‐Or	2018	7
16	Animal models of α-synucleinopathy for Parkinson disease drug development Nature reviews. Neuroscience ·James B. Koprich,Lorraine V. Kalia,Jonathan M. Brotchie	2017	176
17	α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era Trends in Neurosciences ·Naomi P. Visanji,Jonathan M. Brotchie,Lorraine V. Kalia,James B. Koprich,Anurag Tandon,Joel C. Watts,Anthony E. Lang	2016	119
18	Neto1 Is a Novel CUB-Domain NMDA Receptor–Interacting Protein Required for Synaptic Plasticity and Learning PLoS Biology ·David Ng,Graham M. Pitcher,Rachel K. Szilard,Andréa L. Sertié,Marijana Kanisek,Steven J. Clapcote,Tatiana V. Lipina,Lorraine V. Kalia,Daisy T. Joo,Colin McKerlie,Miguel A. Cortez,John Roder,Michael W. Salter,Roderick R. McInnes	2009	141
19	NMDA receptors in clinical neurology: excitatory times ahead The Lancet Neurology ·Lorraine V. Kalia,Suneil K. Kalia,Michael W. Salter	2008	333
20	Src kinases: a hub for NMDA receptor regulationbreakdown → Nature reviews. Neuroscience ·Michael W. Salter,Lorraine V. Kalia	2004	639

About Lorraine V. Kalia

Lorraine V. Kalia is a scholar working on Neurology, Cellular and Molecular Neuroscience and Neurology, having authored 87 papers that have together received 8.9k indexed citations. Recurring topics across this work include Parkinson's Disease Mechanisms and Treatments (44 papers), Neurological disorders and treatments (30 papers), Neuroscience and Neuropharmacology Research (12 papers), Nuclear Receptors and Signaling (12 papers), Genetic Neurodegenerative Diseases (10 papers), Neurological diseases and metabolism (7 papers), Botulinum Toxin and Related Neurological Disorders (6 papers) and Lysosomal Storage Disorders Research (6 papers). The work is most often cited by research in Neurology (4.4k citations), Cellular and Molecular Neuroscience (3.3k citations) and Neurology (1.2k citations). Lorraine V. Kalia has collaborated with scholars based in Canada, United States and Germany. Frequent co-authors include Anthony E. Lang, Michael W. Salter, Suneil K. Kalia, Jonathan M. Brotchie, Pamela J. McLean, Andrés M. Lozano, James B. Koprich, Paul O’Connor, Graham M. Pitcher and Yu Tian Wang. Their work appears in journals such as Nature, The Lancet and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact